Last reviewed · How we verify
TX000045
At a glance
| Generic name | TX000045 |
|---|---|
| Sponsor | Tectonic Operating Company, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (the APEX Study) (PHASE2)
- Study of TX000045 in Participants With Pulmonary Hypertension Due to Interstitial Lung Disease (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TX000045 CI brief — competitive landscape report
- TX000045 updates RSS · CI watch RSS
- Tectonic Operating Company, Inc. portfolio CI